Evidence map›Paper›PMID 26831140›Full record

ArticleBMC infectious diseases2016

Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study.

Gustavo E Velásquez, J Peter Cegielski, Megan B Murray, Martin J A Yagui, Luis L Asencios, Jaime N Bayona, César A Bonilla, Hector O Jave, Gloria Yale, Carmen Z Suárez and 6 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 5 countries.

Gustavo E VelásquezDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA. gvelasquez@bwh.harvard.edu.
J Peter CegielskiDivision of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA, USA. gzc2@cdc.gov.
Megan B MurrayDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA. megan_murray@hms.harvard.edu.
Martin J A YaguiOficina General de Investigación y Transferencia Tecnológica, Instituto Nacional de Salud, Lima, Perú. myaguim2002@yahoo.com.
Luis L AsenciosLaboratorio Nacional de Referencia de Micobacterias, Instituto Nacional de Salud, Lima, Perú. luisasencioss@yahoo.es.
Jaime N BayonaHealth, Nutrition and Population, The World Bank Group, Washington DC, USA. jbayonagarcia@worldbank.org.
César A BonillaEstrategia Sanitaria Nacional de Prevención y Control de la Tuberculosis, Ministerio de Salud del Perú, Lima, Perú. bonasal@gmail.com.
Hector O JaveEstrategia Sanitaria Nacional de Prevención y Control de la Tuberculosis, Ministerio de Salud del Perú, Lima, Perú. rigeljave2008@yahoo.es.
Gloria YaleDirección de Salud V Lima Ciudad, Programa de Control de Tuberculosis, Lima, Perú. gyclab5@yahoo.es.
Carmen Z SuárezDirección de Salud IV Lima Este, Programa de Control de Tuberculosis, Lima, Perú. zoila118@hotmail.com.
Eduardo SanchezServicio de Enfermedades Infecciosas y Tropicales, Hospital Nacional Hipólito Unanue, Lima, Perú. edsanch@gmail.com.
Christian RojasServicio de Neumología, Instituto Nacional Cardiovascular "Carlos Alberto Peschiera Carrillo", Lima, Perú. christeorc@yahoo.com.
Sidney S AtwoodDivision of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA. satwood@partners.org.
Carmen C ContrerasPartners In Health / Socios En Salud, Lima, Perú. ccontreras_ses@pih.org.
Janeth Santa CruzPartners In Health / Socios En Salud, Lima, Perú. jsantacruz_ses@pih.org.
Sonya S ShinDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA. sshin@partners.org.
Brigham and Women's Hospital · USInstituto Nacional de Salud · PEMinisterio de Salud · BOPartners In Health · USCenters for Disease Control and Prevention · USDirección Regional de Salud del Callao · PEEsSALUD · PEHospital Nacional Cayetano Heredia · PENational University of San Marcos · PEWorld Bank · US

Funding

PROGRAM FOR AIDS CLINICAL RESEARCH TRAINING (PACRT)T32AI007433 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MARK J SIEDNER · 1992 to 2026
$11.4M
Evaluation of MDR-TB Treatment Strategies in Lima, PeruK23AI054591 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI SHIN, SONYA S · 2004 to 2006
$331k
NIAID NIH HHS K23 AI054591NIAID NIH HHS L30 AI120170NIAID NIH HHS T32 AI007433
6 · The paper itself

Abstract

backgroundHuman immunodeficiency virus (HIV)-associated tuberculosis deaths have decreased worldwide over the past decade. We sought to evaluate the effect of HIV status on tuberculosis mortality among patients undergoing treatment for tuberculosis in Lima, Peru, a low HIV prevalence setting.

methodsWe conducted a prospective cohort study of patients treated for tuberculosis between 2005 and 2008 in two adjacent health regions in Lima, Peru (Lima Ciudad and Lima Este). We constructed a multivariate Cox proportional hazards model to evaluate the effect of HIV status on mortality during tuberculosis treatment.

resultsOf 1701 participants treated for tuberculosis, 136 (8.0%) died during tuberculosis treatment. HIV-positive patients constituted 11.0% of the cohort and contributed to 34.6% of all deaths. HIV-positive patients were significantly more likely to die (25.1 vs. 5.9%, P < 0.001) and less likely to be cured (28.3 vs. 39.4%, P = 0.003). On multivariate analysis, positive HIV status (hazard ratio [HR] = 6.06; 95% confidence interval [CI], 3.96-9.27), unemployment (HR = 2.24; 95% CI, 1.55-3.25), and sputum acid-fast bacilli smear positivity (HR = 1.91; 95% CI, 1.10-3.31) were significantly associated with a higher hazard of death.

conclusionsWe demonstrate that positive HIV status was a strong predictor of mortality among patients treated for tuberculosis in the early years after Peru started providing free antiretroviral therapy. As HIV diagnosis and antiretroviral therapy provision are more widely implemented for tuberculosis patients in Peru, future operational research should document the changing profile of HIV-associated tuberculosis mortality.

Indexed as

AdultFemaleHIV InfectionsHumansMaleMiddle AgedMultivariate AnalysisPeruPrevalenceProportional Hazards ModelsProspective StudiesTuberculosisYoung Adult

Identifiers

PMID26831140
PMCPMC4736097
OpenAlexW2263802946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.